Tanya Lewis's Insider Trades & SAST Disclosures
Tanya Lewis's most recent trade in DiaMedica Therapeutics Inc was a trade of 28,472 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 1, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Tanya Lewis.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
DiaMedica Therapeutics Inc
|
Tanya Lewis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 28,472 | 28,472 | - | - | Stock Option (right to buy) | |
|
Replimune Group Inc
|
Tanya Lewis | Chief Dev. Op. Officer | Sale of securities on an exchange or to another person at price $ 24.10 per share. | 13 Jun 2023 | 12,043 | 136,110 (0%) | 0% | 24.1 | 290,236 | Common Stock |
|
Replimune Group Inc
|
Tanya Lewis | Chief Dev. Op. Officer | Sale of securities on an exchange or to another person at price $ 23.45 per share. | 13 Jun 2023 | 817 | 135,293 (0%) | 0% | 23.5 | 19,159 | Common Stock |
|
DiaMedica Therapeutics Inc
|
Tanya Lewis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 7,493 | 7,493 | - | - | Stock Option (right to buy) | |
|
Replimune Group Inc
|
Tanya Lewis | Chief Dev. Op. Officer | Sale of securities on an exchange or to another person at price $ 18.05 per share. | 16 May 2023 | 12,207 | 148,153 (0%) | 0% | 18.0 | 220,336 | Common Stock |
|
Replimune Group Inc
|
Tanya Lewis | Chief Dev. Op. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
|
Replimune Group Inc
|
Tanya Lewis | Chief Dev. Op. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 40,000 | 160,360 (0%) | 0% | 0 | Common Stock | |
|
DiaMedica Therapeutics Inc
|
Tanya Lewis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 26,443 | 26,443 | - | - | Stock option (right to buy) | |
|
Replimune Group Inc
|
Tanya Lewis | Chief Dev. Op Officer | Sale of securities on an exchange or to another person at price $ 14.59 per share. | 16 May 2022 | 5,473 | 120,360 (0%) | 0% | 14.6 | 79,851 | Common Stock |
|
Replimune Group Inc
|
Tanya Lewis | Chief Dev.Op Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 78,750 | 78,750 | - | - | Employee Stock Option (right to buy) | |
|
Replimune Group Inc
|
Tanya Lewis | Chief Dev.Op Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 52,500 | 125,833 (0%) | 0% | 0 | Common Stock | |
|
Replimune Group Inc
|
Tanya Lewis | Chief Dev. Oper. Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 110,000 | 110,000 | - | - | Employee Stock Option (right to buy) | |
|
Replimune Group Inc
|
Tanya Lewis | Chief Dev. Oper. Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 73,333 | 73,333 (0%) | 0% | 0 | Common Stock | |
|
Replimune Group Inc
|
Tanya Lewis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 16,500 | 16,500 | - | - | Stock Option (right to buy) | |
|
Karyopharm Therapeutics Inc
|
Tanya Lewis | EVP, Chief Reg. Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 59,968 | 59,968 | - | - | Stock Option (right to buy) | |
|
Karyopharm Therapeutics Inc
|
Tanya Lewis | EVP, Chief Reg. Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 22,013 | 45,401 (0%) | 0% | 0 | Common Stock | |
|
Karyopharm Therapeutics Inc
|
Tanya Lewis | EVP, Chief Reg. Affairs | Sale of securities on an exchange or to another person at price $ 15.52 per share. | 11 Feb 2021 | 2,046 | 4,143 (0%) | 0% | 15.5 | 31,752 | Common Stock |
|
Karyopharm Therapeutics Inc
|
Tanya Lewis | EVP, Chief Reg. Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 5,650 | 6,189 (0%) | 0% | - | Common Stock | |
|
Karyopharm Therapeutics Inc
|
Tanya Lewis | EVP, Chief Reg. Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 5,650 | 16,950 | - | - | Restricted Stock Units | |
|
Replimune Group Inc
|
Tanya Lewis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2020 | 33,000 | 33,000 | - | - | Stock Option (right to buy) | |
|
Karyopharm Therapeutics Inc
|
Tanya Lewis | EVP,Chief Reg.&Quality Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2020 | 765 | 2,295 | - | - | Restricted Stock Units | |
|
Karyopharm Therapeutics Inc
|
Tanya Lewis | EVP,Chief Reg.&Quality Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2020 | 765 | 765 (0%) | 0% | - | Common Stock | |
|
Karyopharm Therapeutics Inc
|
Tanya Lewis | EVP,Chief Reg.&Quality Officer | Sale of securities on an exchange or to another person at price $ 15.58 per share. | 28 Oct 2020 | 226 | 539 (0%) | 0% | 15.6 | 3,521 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges